Skip to main content

Table 1 Characteristics and follow-up of 150 patients with PPBL

From: Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification

Age (years), Mean (min–max) 40 (18.9–66.2)   
Sex (M/F) 26 (17 %)/124 (83 %)   
Tobacco consumption 130/145 (90 %)   
Clinical presentation    
 Lymph node(s) 10/108 (9 %)   
 Splenomegaly 19/106 (18 %)   
 Hepatomegaly 2/108 (2 %)   
Hemogram, Mean (min–max)    
 White blood cells (109/L) 12.8 (7–44.8)   
 Hemoglobin (g/dL) 13.8 (10.1–16.9)   
 Platelets (109/L) 228 (83–380)   
 Lymphocytosis (109/L) 6.5 (2.2–41)   
 Binucleated Lymphocytes (% of lymphocytes) 3.9 (1–40)   
IgM (g/L), Mean (min–max) 7.8 (2.17–20)   
HLA DR7 positive 40/52 (77 %)   
Multiparameter Flow Cytometry—Mean (min–max)    
 CD19 (%) 50.4 (7–83)   
Cytogenetics   Diagnosis Follow-up
 +i(3)(q10) positive by karyotype   50/140 (36 %) 20/32 (63 %)
 +i(3)(q10) positive by FISH   80/128 (63 %) 24/26 (92 %)
 PCC positive   35/140 (25 %) 8/32 (25 %)
 Chromosomal instability   76/140 (54 %) 31/32 (97 %)
Subsequent Malignancies 18/150 (12 %)   
 MGUS 6/150 (4 %)   
 Non-Hodgkin’s Lymphomas 6/150 (4 %)   
 Solid tumors 6/150 (4 %)   
  1. Clinical and biological data were collected from 27 centers. Median follow-up was 60 months (1–402) with unreached median overall survival
  2. MGUS monoclonal gammopathy of undetermined significance